Development and Application of Novel ... - Jacobs University

More documents

Recommendations

Info

PART I: CAPDE mutagenic hotspots generated due to the mutational preferences of the random mutagenesis methods with sequence and structural information of protein. Selecton [42] web server predicts the selective forces at each amino acid position in protein. The server performs the codon-based alignment on a set of the homologous nucleotide sequences and uses the ratio of amino acids altered to silent substitutions (Ka/Ks) to estimate both the positive (>1) and purifying (
PART I: CAPDE The web server performs MSA and ConSurf 2010 [35] calculates evolutionary conservation rate to identify conserved positions in protein or GAL4 transcription factor [35] http://consur f.tau.ac.il/ nucleotide sequence/structure. The database provides ConSurf DB [36] the predicted results of ConSurf [35] server for known protein Cytochrome c [36] http://consur fdb.tau.ac.il/in dex.php structures. Hotspot identificatio n The Evolutionary trace based method performs MSA on a set of homologous sequences DNA polymerase I, DNA transferase, (from PSI-BLAST) after allophycocya Gibbs like sampling. nin, Leucine JET [38] The aligned homologous sequences are used to construct distance tree based on Neighbor Joining dehydrogena se, β-trypsin proteinase, phosphotrans ferase, http://www.i hes.fr/~carbo ne/data6/lege nda.htm algorithm. The human clustering method is CDC42 gene parameterized to regulation identify protein protein, interface or core oncogene residues by taking into protein, 11
Page 1 and 2: Development and Application of Nove
Page 3 and 4: Funding The work described in this
Page 5 and 6: Abstract In the last decades, enzym
Page 7 and 8: Table of Content Acknowledgement ..
Page 9 and 10: 4.5. References ...................
Page 11 and 12: PART I: CAPDE Chapter 1 Computer-Ai
Page 13 and 14: PART I: CAPDE of protein structure
Page 15 and 16: PART I: CAPDE In this chapter, for
Page 17 and 18: PART I: CAPDE library size and rand
Page 19: PART I: CAPDE 1.4. Evolutionary con
Page 23 and 24: PART I: CAPDE based MSA a protein s
Page 25 and 26: PART I: CAPDE name or structure and
Page 27 and 28: PART I: CAPDE for experimental scre
Page 29 and 30: PART I: CAPDE characterizes it bind
Page 31 and 32: PART I: CAPDE stability using inter
Page 33 and 34: PART I: CAPDE in the protein using
Page 35 and 36: PART I: CAPDE Table 1.4: Summarizin
Page 37 and 38: PART I: CAPDE in which the volume o
Page 39 and 40: PART I: CAPDE 21. Chica RA, Doucet
Page 41 and 42: PART I: CAPDE 44. Knoll M, Hamm TM,
Page 43 and 44: PART I: CAPDE 69. Vangone A, Spinel
Page 45 and 46: PART I: CAPDE 95. Emekli U, Schneid
Page 47 and 48: PART I: CAPDE 119. Parthiban V, Gro
Page 49 and 50: PART I: MAP 2.0 3D 2.2. Introductio
Page 51 and 52: PART I: MAP 2.0 3D improve the fitn
Page 53 and 54: PART I: MAP 2.0 3D ⎛ 0.0 9.70 19.
Page 55 and 56: PART I: MAP 2.0 3D amino acid (α)
Page 57 and 58: PART I: MAP 2.0 3D of transformatio
Page 59 and 60: PART I: MAP 2.0 3D amino acid oxida
Page 61 and 62: PART I: MAP 2.0 3D aliphatic amino
Page 63 and 64: PART I: MAP 2.0 3D Figure 2.5, char
Page 65 and 66: PART I: MAP 2.0 3D Figure 2.5: Chem
Page 67 and 68: PART I: MAP 2.0 3D 2.4.2. Phytase P
Page 69 and 70: PART I: MAP 2.0 3D Figure 2.6: MAP
Page 71 and 72:
PART I: MAP 2.0 3D Figure 2.7: Amin
Page 73 and 74:
PART I: MAP 2.0 3D active site resi
Page 75 and 76:
PART I: MAP 2.0 3D (δ(282)Q→ch =
Page 77 and 78:
PART I: MAP 2.0 3D 11. Turner NJ (2
Page 79 and 80:
PART I: MAP 2.0 3D 36. Liao GJ, Lee
Page 81 and 82:
PART II: MD Simulation Chapter 3 In
Page 83 and 84:
PART II: MD Simulation Force field
Page 85 and 86:
PART II: MD Simulation Electrostati
Page 87 and 88:
PART II: MD Simulation 3.4. Structu
Page 89 and 90:
PART II: MD Simulation where vi and
Page 91 and 92:
PART II: P450BM-3 Reductase Domain
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
PART II: P450BM-3 HEME/FMN Complex
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
PART II: P450BM-3 HEME/FMN & CoSep
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
In the second part of the thesis, m
Page 197 and 198:
Curriculum vitae Personal Details N
Page 199:
Statutory Declaration I, RAJNI VERM
show all

Development and Application of Novel ... - Jacobs University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?